ECRI.org Health Technology Forecasthttps://members2.ecri.org/Components/forecast/Copyright 2009 ECRINew and Updated Forecast profilesen-us7/4/2009 3:52:46 PM7/4/2009 3:52:46 PM5htais@ecri.orgFDA approves biologic therapy for rare auto-inflammatory conditionhttps://members2.ecri.org/Components/Forecast/Pages/11575.aspx The U.S. Food and Drug Administration (FDA) recently approved for marketing canakinumab as a first-line treatment for cryoprin-associated periodic syndromes (CAPS), a rare but serious group of autoimmune conditions.7/2/2009Industry analysis firm predicts biotech will overtake pharma by 2014https://members2.ecri.org/Components/Forecast/Pages/11574.aspx The biotech industry will own more slots (7 of 10) on the top-10, best-selling drug list than big pharma by 2014, according to industry analysis firm EvaluatePharma (London, UK).7/2/2009Study uncovers physicians' failure to inform patients about abnormal test resultshttps://members2.ecri.org/Components/Forecast/Pages/11573.aspx Diagnostic processes in primary care physician practices may not always ensure communication to patients about clinically significant findings, according to a new study in Archives of Internal Medicine.7/2/2009Prices fall as another player enters the personal genome services arenahttps://members2.ecri.org/Components/Forecast/Pages/11572.aspx A few years ago, personal genome sequencing was just a dream. Few people thought it would become affordable for the average consumer in the foreseeable future.7/2/2009New antibiotic under development for community-acquired bacterial pneumoniahttps://members2.ecri.org/Components/Forecast/Pages/11571.aspx Preliminary study results on the safety and efficacy of a new antibiotic to treat community-acquired bacterial pneumonia (CABP) were released by Forest Laboratories, Inc.7/2/2009